Clinical Trials Logo

Clinical Trial Summary

Approximately 1.5 million of the 44 million Blacks in the United States are carriers of the valine-to-isoleucine substitution at position 122 (V122I) in the transthyretin (TTR) protein. Virtually exclusive to Blacks, this is the most common cause of hereditary cardiac amyloidosis (hATTR-CA) worldwide. hATTR-CA leads to worsening heart failure (HF) and premature death. Fortunately, new therapies that stabilize TTR improve morbidity and mortality in hATTR-CA, especially when prescribed early in the disease. However, hATTR-CA is often diagnosed at an advanced stage and conventional diagnostic tools lack diagnostic specificity to detect early disease. The overall objectives of this study are to determine the presence of subclinical hATTR-CA and to identify biomarkers that indicate amyloid progression in V122I TTR carriers. The central hypothesis of this proposal is that hATTR-CA has a long latency period that will be detected through subclinical amyloidosis imaging and biomarker phenotyping. The central hypothesis will be tested by pursuing 2 specific aims: Aim 1) determine the association of V122I TTR carrier status with CMRI evidence of amyloid infiltration; Sub-aim 1) determine the association of V122I TTR carrier status with cardiac reserve; Aim 2) determine the association between amyloid-specific biomarkers and V122I TTR carrier status; and Sub-aim 2) determine the association of amyloid-specific biomarkers with imaging-based parameters and evaluate their diagnostic utility for identifying subclinical hATTR-CA. In Aim 1, CMRI will be used to compare metrics associated with cardiac amyloid infiltration between a cohort of V122I TTR carriers without HF formed by cascade genetic testing and age-, sex-, and race-matched non-carrier controls. For Sub-Aim 1, a sub-sample of carriers and non-carrier controls enrolled in Aim 1 will undergo novel exercise CMRI to measure and compare cardiac systolic and diastolic reserve. Aim 2 involves measuring and comparing amyloid-specific biomarkers in V122I TTR carriers without HF with samples matched non-carriers (both from Aim 1) and individuals with symptomatic V122I hATTR-CA from our clinical sites. These biomarkers detect and quantify different processes of TTR amyloidogenesis and include circulating TTR, retinol binding protein 4, TTR kinetic stability, and misfolded TTR oligomers. Sub-aim 2 will establish the role of these biomarkers to detect imaging evidence of subclinical hATTR-CA disease.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05489549
Study type Observational
Source University of Texas Southwestern Medical Center
Contact Amy Browning
Phone 214-645-8040
Email Amy.Browning@utsouthwestern.edu
Status Recruiting
Phase
Start date November 21, 2022
Completion date June 30, 2027

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04985734 - Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral Neuropathy N/A
Enrolling by invitation NCT05718401 - The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based Metabolomics
Recruiting NCT05167799 - Cardiac Contractility Modulation Therapy in Amyloid Cardiomyopathy Patients With Heart Failure
Completed NCT03996382 - Prevalence of Wild Type Transthyretin Cardiac Amyloidosis in Patients Operated for Idiopathic Carpal Tunnel Syndrome N/A
Recruiting NCT06066632 - Analysis of Calcium Score of Severe Aortic Stenosis in Patients With and Without Cardiac Amyloidosis (CAUSATIVE Study)
Recruiting NCT05379101 - Intracardiac Flow Assessment in Cardiac Amyloidosis
Recruiting NCT06186167 - Amyloidosis Incidence in High-Risk Cardiac Device Patients
Recruiting NCT06251778 - NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis
Recruiting NCT03984877 - Impact of Amyloidosis on TAVI Patients
Completed NCT04298372 - Frontline Lenalidomide for AL Amyloidosis Involving Myocardium Phase 3
Not yet recruiting NCT05938218 - Virtual Reality Assisted Patient Empowerment: Diagnose ATTR-Amyloidosis And Start Treatment N/A
Recruiting NCT04667494 - Ultrasound Therapy In Cardiac Amyloidosis Phase 4
Active, not recruiting NCT04061213 - ATTR Amyloidosis in Elderly Patients With Aortic Stenosis
Recruiting NCT04587648 - Cardiac Amyloidosis in HFpEF